Tildrakizumab (SCH 900222) is a humanized anti-IL-23 (p19 subunit) monoclonal antibody. IL-23 is a critical cytokine to maintain the Th17 cell phenotype. Tildrakizumab has high-affinity for single-chain IL-23 (Kd: 136 pM). Tildrakizumab is effective against moderate to severe plaque psoriasis.
Purity:
>99.0%
CAS Number:
[1326244-10-3]
Target:
IL Receptor/Related
* VAT and and shipping costs not included. Errors and price changes excepted